ArticleCureus2025
Eligible but Untreated: Gaps in Statin Therapy for Type 1 Diabetes Under the National Institute for Health and Care Excellence (NICE) Guidelines.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Type 1 Diabetes and Cardiovascular Risk: The Current Management Strategies.Reviews in cardiovascular medicine · 2026Review
- Patients with type 1 diabetes mellitus and recommended low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B targets - a SwissDiab study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Cardiovascular disease (CVD) represents a principal contributor to premature morbidity and mortality in individuals with type 1 diabetes mellitus (T1DM). Effective lipid management, including the use of statin therapy, offers substantial potential to mitigate long‑term vascular risk, particularly among patients with established microvascular complications or long disease duration. This study aimed to assess the extent to which statin prescribing practices in a large healthcare trust align with the current National Institute for Health and Care Excellence (NICE) guidelines. Methods We performed a retrospective review of electronic health records for T1DM patients under the care of a single healthcare trust. Patients were stratified into two groups based on age: ≥40 years and <40 years. According to NICE criteria, statin therapy is indicated for patients aged ≥40 years, or those of any age with diabetes duration >10 years, diabetic nephropathy, or other modifiable cardiovascular risk factors. The main outcome measure was the proportion of eligible patients who had been prescribed statin therapy. Data were analyzed using descriptive statistics. Results Among 1,229 patients aged ≥40 years, 896 (73%) were receiving statins, leaving 333 (27%) without therapy despite being eligible. In the <40 years age group, 192 patients met NICE indications for statin use. Prescription rates were notably lower in this cohort: six (35%) for those with nephropathy, 2two(15%) among those with retinopathy, and 75 (47%) for patients with both risk factors. Overall, only 83 (43%) of eligible patients under 40 were prescribed statins. Conclusions Our findings reveal a significant gap between guideline recommendations and real-world prescribing patterns, particularly among younger T1DM patients with additional CVD risk factors. Given the elevated cardiovascular risk in this population, strategies to enhance clinician awareness and improve adherence to NICE guidance are urgently needed to optimize primary prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.